$1.19
N/A
At close: Nov 13, 4:00 PM EST
$1.18
-0.01-0.84%
After Hours: Nov 13, 7:25 PM EST
MaxCyte Inc
MXCTNASDAQ
MaxCyte (MXCT) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 10, 2026 | $-0.05 | $-0.08 | 37.5 % |
| Q2 | Aug 12, 2026 | $-0.08 | $-0.10 | 20.0 % |
| Q1 | May 12, 2026 | $-0.04 | $-0.09 | 55.6 % |
| Q4 | Mar 24, 2026 | $-0.09 | $-0.08 | -12.5 % |
Quarterly Revenue (Billions)
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 10, 2026 | $10.15M | $7.36M | 38.0 % |
| Q2 | Aug 12, 2026 | $7.27M | $6.47M | 12.3 % |
| Q1 | May 12, 2026 | $9.65M | $7.31M | 32.0 % |
| Q4 | Mar 24, 2026 | $7.30M | $9.16M | -20.3 % |
MaxCyte (MXCT) last issued guidance on November 10, 2026 for fiscal year 2026. The company guided revenue in the range of for the period.
Compared to prior guidance, MaxCyte raised its revenue forecast from a prior range of $30M - $32M.
MaxCyte has issued 27 guidance updates between March 6, 2023 and October 14, 2026. During this period, the company raised its outlook 7 times and lowered it 12 times, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.08 | $-0.10 | $-0.09 | $-0.08 |
| Actual | $-0.05 | $-0.08 | $-0.04 | $-0.09 |
| Surprise | +37.5% | +20.0% | +55.6% | -12.5% |
| Revenue | ||||
| Estimate | $7.4M | $6.5M | $7.3M | $9.2M |
| Actual | $10.2M | $7.3M | $9.7M | $7.3M |
| Surprise | +38.0% | +12.3% | +32.0% | -20.3% |
| Metric | Q4 '26E | Q1 '27E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $-0.06 | $-0.07 |
| Revenue | ||
| Consensus | $8.0M | $8.1M |
